Diamond Wipes International is recalling CVS Health Medicated Hemorrhoidal Wipes because the lidocaine-containing product was sold without child-resistant packaging, creating what the U.S. Consumer Product Safety Commission describes as a risk of serious injury or death from child poisoning. The recall highlights a specific failure in the supply chain: the packaging shipped to consumers did not meet a federal standard that has been on the books for decades, and the product reached store shelves anyway.
Lidocaine wipes and the child-resistant packaging gap
The core problem is straightforward. Lidocaine is a topical anesthetic that can cause seizures, cardiac arrest, and death in young children who ingest it. The CPSC extended child-resistant packaging requirements to topical medications containing more than 5.0 mg of lidocaine per package after a 1994 rulemaking that cited injury and death data involving children. CVS Health Medicated Hemorrhoidal Wipes contain lidocaine and fall squarely under that rule. Yet the product’s packaging was not child-resistant.
Under the Poison Prevention Packaging Act, importers and domestic packagers bear direct responsibility for certifying that regulated products meet federal standards. That certification must be supported by testing data following protocols spelled out in CPSC compliance guidance. The performance thresholds themselves are defined in 16 CFR 1700.15, which sets how resistant packaging must be to opening by children under five. Diamond Wipes International, as the entity conducting the recall, held the compliance obligation for this product.
What the CPSC recall record shows about Diamond Wipes
The federal recall listing on the CPSC’s recalls page identifies the hazard plainly: the wipes violate a mandatory standard for child-resistant packaging under the Poison Prevention Packaging Act. The CPSC classifies the risk level as serious injury or death from child poisoning. No public incident or injury reports tied to this specific product have been disclosed in the recall announcement.
The recall raises a pointed question about how the product cleared distribution without proper packaging. Federal rules place the compliance burden on the importer or domestic packager, not the retailer. Diamond Wipes International, which manufactures wipes for multiple brands, was responsible for ensuring the packaging met 16 CFR 1700.15 testing thresholds before the product shipped. The fact that it did not suggests a breakdown either in the company’s quality-control process or in its pre-market certification testing.
In addition to certifying compliance, companies are expected to maintain documentation that packaging has been tested using panels of children and adults, following methods laid out by the CPSC. Those tests are designed to demonstrate that most young children cannot open a package within a specified time, while adults can do so without unusual difficulty. When a product like a lidocaine wipe fails to use this type of packaging, it indicates that either the testing was never done, the wrong packaging was substituted later in the supply chain, or a failure in oversight allowed non-compliant components to be used.
Unanswered questions about testing and enforcement
Several details are missing from the public record. The CPSC recall notice does not specify how many units were sold, how long the non-compliant product was on shelves, or whether the agency discovered the violation through its own surveillance or a company self-report. No injury reports from the CPSC’s public database have been linked to this recall. The CPSC’s Office of Inspector General has not publicly disclosed any audit findings related to Diamond Wipes International’s compliance practices, leaving open how the lapse was first identified.
What is clear is that the underlying legal framework is not new. The Poison Prevention Packaging Act has long required child-resistant closures for a range of hazardous household substances, including certain oral and topical drugs. The 1994 expansion to lidocaine products was specifically intended to prevent poisonings from easily opened tubes, bottles, and similar containers. In that context, the failure to apply child-resistant standards to medicated wipes appears less like a gray area and more like a straightforward compliance miss.
The recall also underscores the limits of relying on market incentives alone to enforce safety rules. Retailers and consumers typically assume that products on shelves already meet federal standards. When a basic packaging safeguard is absent, the problem may only surface after an internal review, a regulatory inspection, or a near-miss incident. Without more transparency about how this recall came about, it is difficult to know whether the issue was an isolated oversight or a symptom of broader weaknesses in how contract manufacturers manage regulated packaging.
For consumers, the practical guidance is simple: any product containing lidocaine or other potent active ingredients should be stored out of children’s reach, even when child-resistant packaging is present. For manufacturers and importers, the episode is a reminder that packaging is not a cosmetic detail but a core element of regulatory compliance. As lidocaine and other topical anesthetics continue to be incorporated into over-the-counter products, the effectiveness of these long-standing packaging rules will depend on how rigorously companies like Diamond Wipes International test, certify, and monitor the materials they send into the marketplace.
